MJNA - Medical Marijuana, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0380
-0.0004 (-1.04%)
As of 12:44PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0384
Open0.0400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0361 - 0.0400
52 Week Range0.0361 - 0.1100
Volume2,400,649
Avg. Volume5,390,192
Market Cap216.478M
Beta (3Y Monthly)-2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.0140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Announces Super Academy Event and Product Launch in Amsterdam

    SAN DIEGO, Sept. 19, 2019 /PRNewswire/ -- Medical Marijuana, Inc. ("the Company") (MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that its subsidiary Kannaway® is hosting a Super Academy event in Amsterdam on Sept. 27-29. The event will give Kannaway®'s European Brand Ambassadors the opportunity to network with top Kannaway® Europe leaders, the Company's global executive team and fellow business owners. The Brightfield Group predicts that "impending regulatory changes" will drive Europe's CBD market from $318 million last year to $416 million in 2019, and also projects that market will surge 400% to $1.7 billion by 2025.

  • Market Exclusive

    AXIM to Launch CBD Chewing Gum to Treat Chemotherapy Symptoms

    Medical Marijuana (OTC: MJNA) announced that its major investment company AXIM Biotechnologies (OTCQB: AXIM) is making its cannabinoid-based chewing gum to treat chemotherapy-related symptoms. The chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC), is being manufactured through AXIM's contract manufacturer Eurofins Amatsigroup in Belgium. It will be used in AXIM's upcoming clinical studies on cannabis as a treatment […]The post AXIM to Launch CBD Chewing Gum to Treat Chemotherapy Symptoms appeared first on Market Exclusive.

  • PR Newswire

    Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Signs Agreement with Online Marketplace Dr. Cannabis

    SAN DIEGO, Sept. 17, 2019 /PRNewswire/ -- Medical Marijuana, Inc. ("the Company") (MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that its subsidiary HempMeds® Brasil, the first Anvisa-authorized company to import cannabidiol (CBD)-based medicines in the country, has signed a partnership agreement for Dr. Cannabis, an online marketplace that facilitates patient access to medical cannabis, to become the exclusive Brazilian reseller of the Company's CBD products. Since 2014, almost 10,000 authorizations have been granted to individual patients, allowing them to import medical cannabis on a case-by-case basis, each for a period of up to one year.

  • PR Newswire

    Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies

    SAN DIEGO , Sept. 12, 2019 /PRNewswire/ --  Medical Marijuana, Inc . (OTC: MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's ...

  • PR Newswire

    HempMeds®, Subsidiary of Medical Marijuana, Inc., Announces Presence at Natural Products Expo East

    SAN DIEGO, Sept. 10, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® will be attending and exhibiting at Natural Products Expo East in Baltimore, Maryland, on Sept. 11-14. According to a 2019 report by Natural Food Merchandiser magazine, the Natural Products Market produced over $158 million in sales in 2018 and is projected to grow by 49 percent in 2019. At the conference, HempMeds® will exhibit its well-trusted hemp-derived CBD lifestyle brands such as its Real Scientific Hemp Oil™ and Dixie Botanicals® as well as the Company's Personal Care Line of hair and skincare products, Everyday Wellness Line of functional products and brand new pet products.

  • PR Newswire

    Medical Marijuana, Inc. and Subsidiary Dixie Botanicals® Secure National News Coverage in Leading Financial Publication Benzinga

    SAN DIEGO , Sept. 3, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever ...

  • Benzinga

    The Week In Cannabis: Moves From The DEA, FDA, USDA; New York Fashion Week; And Quarterly Reports

    A series of earnings reports from big companies including Slang Worldwide Inc (OTC: SLGWF) and TILT Holdings Inc (OTC: SVVTF) provided evidence that “the slow rollout of Massachusetts' recreational licenses has finally hit the earnings of cannabis companies who were slow to recognize the effects,” Green Market Report CEO Debra Borchardt told Benzinga. In other news, we found out that a weed-themed show is hitting the runway at the New York Fashion Week, the product of a collaboration between bold fashion designer Korto Momolu —featured on the show "Project Runway" —and Women Grow, the largest networking organization for women in the cannabis and hemp industries. "To sum it up in one phrase: it's 'for women, by women,'" Momolu told Benzinga.

  • Market Exclusive

    Cannabis Stock News Daily Roundup August 27

    iAnthus Capital Holdings (CSE: IAN) (OTCQX: ITHUF) reported its financial results for the fiscal second quarter ended June 30. Revenue for the quarter was $19.20 million, up from $256,000 for the same period of last year. The company posted a loss of $9.29 million, or $0.06 loss per share, versus a loss of $35.44 million, or […]The post Cannabis Stock News Daily Roundup August 27 appeared first on Market Exclusive.

  • HempMeds®, Subsidiary of Medical Marijuana, Inc., Releases Hemp for Pets Product Line in Celebration on National Dog Day
    PR Newswire

    HempMeds®, Subsidiary of Medical Marijuana, Inc., Releases Hemp for Pets Product Line in Celebration on National Dog Day

    SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® has released its Hemp for Pets pet cannabidiol (CBD) product line in celebration of National Dog Day. Hemp for Pets by HempMeds® was created to help improve the lives of all pets, from nose to tail. The Company, a proud member of the National Pet Supplement Council (NPSC), aims to improve the lives of pets and people naturally with a commitment to ethically-sourced hemp CBD extract and natural ingredients, dedicated scientific expertise and innovation backed by the strictest efficacy testing.

  • PR Newswire

    Medical Marijuana, Inc. Listed as a Top 5 Company in Hemp-Based CBD Market by Equity Research Firm Avise Analytics

    SAN DIEGO, Aug. 22, 2019 /PRNewswire/ -- Medical Marijuana, Inc. ("the Company") (MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that equity research firm Avise Analytics, Ltd. ("Avise Analytics") ranked the Company as one of the Top 5 Companies in the Hemp-Based Cannabidiol (CBD) Market. "It is an honor to once again be recognized as a leader in the cannabis industry and specifically the CBD market," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. Avise Analytics, founded in 2012, is an international provider of high-quality research and offers a comprehensive range of customized equity research outsourcing services, investment, financial and credit research outsourcing solutions.

  • Benzinga

    Everyday CBD: Sun, Sand, And SeaBD

    If you’ve been paying attention to the sunscreen scene of late, you’ve probably seen how tropical destinations like Hawaii and Key West are banning common sunscreen chemicals oxybenzone and octinoxate since they damage delicate marine ecosystems. According to Punjabi, the benefits center around the anti-inflammatory properties of CBD, which can help “almost every skin condition you can think of—from eczema to acne.” Since the skin doesn’t absorb CBD as well as inhaling or ingesting it—which allows it to enter the bloodstream—CBD-based skincare products are a great “gateway” product for consumers new to the hemp industry.

  • Medical Marijuana, Inc. and Subsidiary Kannaway® Honored as Stevie® Award Winners in 2019 International Business Awards®
    PR Newswire

    Medical Marijuana, Inc. and Subsidiary Kannaway® Honored as Stevie® Award Winners in 2019 International Business Awards®

    SAN DIEGO, Aug. 20, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company was named the winner of a Bronze Stevie® Award in the Most Innovative Company of the Year – Up to 100 Employees category in The 16th Annual International Business Awards. "Medical Marijuana, Inc. has been devoted to innovating all aspects of the CBD industry since new management took control in March 2011," said Medical Marijuana, Inc. CEO Dr. Stuart Titus.

  • PR Newswire

    Medical Marijuana, Inc. Reports $20.7 Million in Revenue in Q2 2019, Up 30% Year-Over-Year in Financial Results

    SAN DIEGO , Aug. 15, 2019 /PRNewswire/ --  Medical Marijuana, Inc.  (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's ...

  • GlobeNewswire

    Medical Marijuana, Inc. Announces Second Quarter Filing Date and Schedules Investor Conference Call for August 15, 2019

    Medical Marijuana, Inc. (MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that the Company will file its second quarter financial and operational results on August 14 and will host an investor conference call at 4:30 PM ET on Thursday, Aug. 15, to discuss earnings for the quarter ending June 30, 2019. Medical Marijuana, Inc. CEO Dr. Stuart Titus and COO Blake Schroeder will provide updates on the financial and operational performance of the Company in the second quarter of 2019, share recent research and development progress, and discuss where the company is headed for the remainder of the year and in the future.

  • Medical Marijuana, Inc. Subsidiary Dixie Botanicals® Announces Launch of Watermelon-Flavored CBD Gummies
    PR Newswire

    Medical Marijuana, Inc. Subsidiary Dixie Botanicals® Announces Launch of Watermelon-Flavored CBD Gummies

    SAN DIEGO , Aug. 7, 2019 /PRNewswire/ --  Medical Marijuana, Inc . (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived ...

  • Benzinga

    CBD And Chemotherapy-Induced Peripheral Neuropathy: What Science Tells Us

    A recent study revealed research findings around chemotherapy-induced peripheral neuropathy, or CIPN, and the potential for CBD as a treatment. The study, conducted by Kannalife, a company in the Medical Marijuana Inc (OTC: MJNA) portfolio, and published in the Journal of Molecular Neuroscience, showed that both CBD and the company's proprietary CBD-like molecule, KLS-13019, had protective action on the mitochondrial exchanger known to increase calcium levels — and therefore neuropathic pain — in patients taking the chemotherapy drug paclitaxel. It's actually a greater difference in potency," said Dr. Doug Brenneman, Kannalife's lead scientist.

  • PR Newswire

    Medical Marijuana, Inc. Subsidiaries HempMeds®, HempMeds® Mexico and HempMeds® Brasil Announce July 2019 as the Largest Sales Bookings Month in Company History

    SAN DIEGO , Aug. 6, 2019 /PRNewswire/ --  Medical Marijuana, Inc.  (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's ...

  • PR Newswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Enters Strategic Partnership With Endocanna Health to Create and Sell Endocannabinoid DNA Test Products

    SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) (the "Company"), the first publicly traded cannabis company in the United States that launched the world's preeminent cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has entered a strategic partnership with Endocanna Health, Inc., ("Endocanna") a research and development biotechnology company specializing in endocannabinioid DNA testing and personalization. Kannaway® and Endocanna will collaborate on the development and distribution of endocannabinoid DNA test products. Under the terms of the agreement, Endocanna will manufacture its patent-pending Endocannabinoid DNA Test Kits (the "Kits") and license its proprietary DNA technology to Kannaway®.

  • GlobeNewswire

    Medical Marijuana, Inc. Begins Manufacturing Operations Under An Industrial Hemp Processor License

    Medical Marijuana, Inc. (MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company has begun manufacturing operations under an industrial hemp processor license. This processor license will allow Medical Marijuana, Inc. to freely store, handle and convert industrial hemp into a marketable form.

  • GlobeNewswire

    Medical Marijuana, Inc. Opens New Production & Warehousing Facility to Expedite International Expansion Efforts

    Medical Marijuana, Inc. (MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today the expansion of its operations with a new production and warehouse facility. The facility has been designed to help the Company increase warehousing, fulfillment and production activities related to the Company’s CBD hemp oil products.

  • PR Newswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Grows International Leadership Team With Janne Heimonen as Managing Director of European Division

    SAN DIEGO, July 17, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that that its subsidiary Kannaway® has appointed Janne Heimonen as Managing Director of its burgeoning European Division. Kannaway® currently ships its products to many countries within the EU. The company is working to expand access to CBD and hemp throughout Europe and has grown to a nearly $40 million revenue run rate since its official launch in 2018.

  • PR Newswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Announces Updated Branding Strategy and Website to Expand Consumer Reach

    SAN DIEGO, July 11, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that its subsidiary Kannaway® has launched a completely redesigned website and the rebranding of its globally recognized hemp-derived cannabidiol (CBD) products. Through its newly designed consumer-driven website, the Company hopes that consumers will find it easier to navigate for access to the products and CBD education that fits their unique lifestyles.

  • PR Newswire

    Medical Marijuana, Inc. and Subsidiaries Kannaway® and HempMeds® Announce June 2019 as the Largest Sales Bookings Month in Company History

    - Medical Marijuana, Inc. completed the first-ever high-level stability study on a cannabidiol (CBD) hemp oil product - Subsidiary Kannaway® began pre-marketing initiatives in Japan ahead of significant ...

  • PR Newswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Announces European Industrial Hemp Association Membership

    SAN DIEGO, July 2, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has become a member of the European Industrial Hemp Association (EIHA) and will participate in the organization's operational and legislative activities.

  • PR Newswire

    Medical Marijuana, Inc. Issues Letter to Shareholders

    SAN DIEGO, June 27, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that it has issued a letter to its shareholders, providing commentary on the Company's recent financial and operational results and upcoming objectives. Overview of the Company's "One Plant | Three Initiatives" approach to capitalize on the growing industrial hemp and CBD industries by being a global house of brands, leader in research and development of cannabinoid-based therapeutics, and worldwide supplier of high-quality CBD raw materials. Commentary on the Company's financial progress and recent financial results, which included record gross sales, increased gross profit, decreases in operating expenses as a percentage of sales, and a non-GAAP financial analysis including adjusted EBITDA for the most recent quarter.